Difference between revisions of "Mitomycin (Mutamycin)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Mesothelioma medications" to "Category:Malignant pleural mesothelioma medications") |
||
| Line 53: | Line 53: | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Head and neck cancer medications]] | [[Category:Head and neck cancer medications]] | ||
| − | [[Category: | + | [[Category:Malignant pleural mesothelioma medications]] |
[[Category:Non-small cell lung cancer medications (historic)]] | [[Category:Non-small cell lung cancer medications (historic)]] | ||
Revision as of 16:41, 1 May 2022
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anal cancer
- Bladder cancer
- Cervical cancer
- Cholangiocarcinoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Head and neck cancer
- Mesothelioma
Diseases for which is was used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/24/1981: Initial FDA approval
Also known as
- Generic names: mitomycin-C, MTC
- Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin
References
Categories:
- Drugs
- Intravenous medications
- Intravesical medications
- Vesicant
- Antitumor antibiotics
- Human DNA synthesis inhibitors
- Anal cancer medications
- Bladder cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Malignant pleural mesothelioma medications
- Non-small cell lung cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1981